Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on June 25, 2024. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice:
- Stock Price Deficiency: The closing bid price of the Company's common stock was below $1.00 per share for the last 30 consecutive business days prior to June 25, 2024.
Material Changes
The primary material event is the receipt of a delisting deficiency notice from Nasdaq. The Company failed to meet the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). No other material changes to operations or financial status are detailed in this specific filing.
Guidance, Outlook, and Risks
Compliance Timeline: The Company has been granted an initial compliance period of 180 calendar days, ending on December 23, 2024.
Path to Compliance: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date.
Contingencies and Risks:
- If the Company fails to regain compliance by December 23, 2024, it may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
- If the Company fails to regain compliance and is not eligible for an extension, Nasdaq will issue a delisting notice.
- The Company may appeal a delisting determination to the Nasdaq Listing Qualifications Panel, though success is not assured.
Management Commentary: The Company intends to actively monitor the closing bid price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of APVO common stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if the initial compliance requirement is met.
- Review upcoming filings for announcements regarding a potential reverse stock split if the price does not recover naturally.
- Check the Company's market value of publicly held shares to determine eligibility for a second compliance period if the first is missed.